Therapeutical Class：3rd generation cephalosporins, inhibit cell wall synthesis by inhibiting the final transpeptidation step of peptidoglycan synthesis

Indication：G(+): half as active as cefotaxime, not for Enterococci, MRSA, Listeria; G(-): Enterobacteriaceae (=cefotaxime), P. aeruginosa (>cefoperazone, piperacillin), Acinetobacter, not for Campylobacter.

Administraton：IM or IV.

Adults: 500 mg-2 g q8-12h.

Severe infections including meningitis, complicated pneumonia, CNS infection, osteomyelitis, intra-abdominal and gynecological , skin and soft tissue: 2 g q8h. Renal impairment: Ccr 31-50 ml/min, administer q12h;

Ccr 10-30 ml/min, administer q24h;

Ccr <10 ml/min, administer q48-72h.

Children: <1 month, 30 mg/kg q12h; >1 month,30-50 mg/kg/dose q8h, max 6 g/day.

Adverse Effect：Phlebitis, pain at injection site (1-10%), neutropenia, thrombocytopenia, diarrhea (1-10%), elevated AST, ALT and BUN.

Pregnancy Risk：BSupply：Tatumcef XE “Tatumcef”  For IV Inj 2gm（祐坦賜福乾粉注射劑 中化）＜02358＞